期刊文献+

HPLC法测定地西他滨中L-异构体和α-异构体含量 被引量:1

Determination of L-isomer and α-isomer in Decitabine by HPLC
下载PDF
导出
摘要 目的建立高效液相法对地西他滨中L-异构体和α-异构体进行拆分并检测其中异构体含量。方法色谱柱采用CHIRACPAK-ADH手性柱(250mm×4.6mm,5μm);流动相:无水乙醇一正己烷(50∶50);流速:0.5m L·min^(-1);检测波长:244nm;进样量:20μL。结果本法对L-异构体和α-异构体的分离度为2.42,地西他滨浓度在0.395~4.02μg·m L^(-1)范围内呈良好的线性关系(r=0.9999),L-异构体浓度在0.419~4.04μg·m L^(-1)范围内呈良好的线性关系(r=0.9997),α-异构体浓度在0.419~4.02μg·m L^(-1)范围内呈良好的线性关系(r=0.9998),检测限分别为5.10ng和5.08ng,平均回收率分别为98.47%和99.22%。结论该方法操作简便,分离效果好,可用于地西他滨中异构体的含量测定。 OBJECTIVE To establish an HPLC method for separation of the L-and α-decitabine and determination of the L-and-α isomer. METHODS The separation was performed on a CHIRACPAK-ADH chiral column( 250 mm × 4. 6mm,5μm). Absolute alcohol and n-hexane( 50∶ 50) was used as mobile phase. The flow rate was0. 5m L· min(-1). The detection wavelength was set at 244 nm. The injection volume was 20μL. RESULTS This method showed that the resolution of the L-and-α isomer was 2. 42,the calibration curve was liner within the range of0. 395 - 4. 02μg· m L(-1)( r = 0. 9999) for decitabine,the calibration curve was liner within the range of 0. 419 -4. 04μg·m L(-1)( r = 0. 9997) for L-isomer,the calibration curve was liner within the range of 0. 419 - 4. 02μg·m L(-1)( r = 0. 9998) for α-isomer,the L-isomer detection limit was 5. 10 ng,the α-isomer detection limit was 5. 08 ng,the average recovery rate was 98. 47% and 99. 22%. CONCLUSION The method is simple and effective. It can be used for content determination of L-and-α-isomer in decitabine.
出处 《海峡药学》 2016年第4期83-85,共3页 Strait Pharmaceutical Journal
关键词 地西他滨 HPLC法 L-异构体 α-异构体 含量测定 Decitabine HPLC method L-isomer α-isomer Content determination
  • 相关文献

参考文献5

二级参考文献17

  • 1Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res, 1997,25:225
  • 2Ingelse BA, Everaerts FM, Sevcik J, et al. A further study on the chiral separation power of a soluble neutral β - cyclodextrin polymer. J High Resol Chromatogr, 1997,18:348
  • 3Tanaka M, Banba M, Joko A, et al. Pharmacological and therapeutic properties of lafutidine( stogar and protecadin) ,a novel histamine H2 receptor antagonist with gastroprotective activity. Nippon Yakurigaku Zasshi,2001,117 :377
  • 4Blackwell CP, Harding SM. The clinical pharmacology of ondansetron. Eur J Cancer Clln Oncol, 1989,25 ( Suppl 1 ) : S21 ; discussion S25
  • 5Liu J,Stewart JT. High - performance liquid chromatographic analysis of ondansetron enantiomers in human serum using a reversed - phase cellulose - based chiral stationary phase and solid - phase extraction. J Chromatogr B,1997,694:179
  • 6Kelly JW, He L, Stewart JT. High - performance liquid chromatographic separation of ondansetron enantiomers in serum using a cellulose - derivatized stationary phase and solid - phase extraction. J Chromatogr B, 1993,622 : 291
  • 7Siluveru M,Stewart JT. Enantiosdective determination of S - ( + ) -and R - ( - ) - ondansetron in human serum using derivatized cyclodextrin - modified capillary electrophoresis and solid - phase extraction. J Chromatogr B, 1997,691:217
  • 8James Ogden. The Organic Chemistry Problem Solver. New Jersey,USA : Research & Education Assoc ,2001. 825
  • 9Chirobiotic Handbook. Advanced Separation Technologies. 5th ed.Whippany, USA. 2004.1
  • 10Hermasson J. Enantiomeric separation of drugs and related compounds based on their interaction with α1-acid glycoprotein. Trends Anal Chem,1989,8:251

共引文献16

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部